News

FDA Grants Fast Track Designation to PWS Potential Therapy LV-101

The U.S. Food and Drug Administration (FDA) has granted fast track designation to LV-101 (intranasal carbetocin), a treatment candidate for people with Prader-Willi syndrome (PWS). This designation is granted to promising therapies intended to treat serious diseases with unmet medical needs. It aims to quicken treatment development by…

Daily Probiotic Reduces Abdominal Fat and Insulin Resistance in Children with PWS, Study Finds

Daily consumption of a common probiotic significantly lowered the percentage of abdominal fat, improved insulin resistance, and reduced social withdrawal in patients with Prader-Willi syndrome, a study has found. The research, “Effects of Bifidobacterium animalis subsp. lactis on children with Prader-Willi syndrome: A randomized, double-blind, placebo-controlled, crossover trial,”…

Long-term Growth Hormone Treatment Not Linked with Increased Severity of Scoliosis in Children with PWS, Study Finds

Treatment with growth hormone for eight years led to a lower spine curvature in children with Prader-Willi syndrome (PWS) who developed scoliosis, a preliminary Dutch study reports. The research, “Effects of eight years growth hormone treatment on the onset and progression of scoliosis in children with Prader-Willi syndrome,”…